title: Injectable perlecan domain 1-hyaluronan microgels potentiate the cartilage repair effect of BMP2 in a murine model of early osteoarthritis.
abstract: The goal of this study was to use bioengineered injectable microgels to enhance the action of bone morphogenetic protein 2 (BMP2) and stimulate cartilage matrix repair in a reversible animal model of osteoarthritis (OA). A module of perlecan (PlnD1) bearing heparan sulfate (HS) chains was covalently immobilized to hyaluronic acid (HA) microgels for the controlled release of BMP2 in vivo. Articular cartilage damage was induced in mice using a reversible model of experimental OA and was treated by intra-articular injection of PlnD1-HA particles with BMP2 bound to HS. Control injections consisted of BMP2-free PlnD1-HA particles, HA particles, free BMP2 or saline. Knees dissected following these injections were analyzed using histological, immunostaining and gene expression approaches. Our results show that knees treated with PlnD1-HA/BMP2 had lesser OA-like damage compared to control knees. In addition, the PlnD1-HA/BMP2-treated knees had higher mRNA levels encoding for type II collagen, proteoglycans and xylosyltransferase 1, a rate-limiting anabolic enzyme involved in the biosynthesis of glycosaminoglycan chains, relative to control knees (PlnD1-HA). This finding was paralleled by enhanced levels of aggrecan in the articular cartilage of PlnD1-HA/BMP2-treated knees. Additionally, decreases in the mRNA levels encoding for cartilage-degrading enzymes and type X collagen were seen relative to controls. In conclusion, PlnD1-HA microgels constitute a formulation improvement compared to HA for efficient in vivo delivery and stimulation of proteoglycan and cartilage matrix synthesis in mouse articular cartilage. Ultimately, PlnD1-HA/BMP2 may serve as an injectable therapeutic agent for slowing or inhibiting the onset of OA after knee injury.
authors.affiliation: Department of Biological Sciences, University of Delaware, Newark, DE, USA.
authors.forename: Padma P
authors.initials: PP
authors.lastname: Srinivasan
authors.forename: Sarah Y
authors.initials: SY
authors.lastname: McCoy
authors.forename: Amit K
authors.initials: AK
authors.lastname: Jha
authors.forename: Weidong
authors.initials: W
authors.lastname: Yang
authors.forename: Xinqiao
authors.initials: X
authors.lastname: Jia
authors.forename: Mary C
authors.initials: MC
authors.lastname: Farach-Carson
authors.forename: Catherine B
authors.initials: CB
authors.lastname: Kirn-Safran
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage* / Q000737:chemistry; D002356:Cartilage / Q000187:drug effects* / Q000473:pathology; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000138:chemical synthesis*; D019812:Heparan Sulfate Proteoglycans / Q000737:chemistry*; D006820:Hyaluronic Acid / Q000737:chemistry*; D020100:Hydrogels / Q000138:chemical synthesis; D007270:Injections, Intra-Articular; D051379:Mice; D008810:Mice, Inbred C57BL; D010003:Osteoarthritis / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: C525719:Bmp2 protein, mouse; D055396:Bone Morphogenetic Protein 2; D003692:Delayed-Action Preparations; D019812:Heparan Sulfate Proteoglycans; D020100:Hydrogels; C071927:perlecan; D006820:Hyaluronic Acid